{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:20:19Z","timestamp":1791069619665,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.lpm.2011.09.001","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T03:43:40Z","timestamp":1318477420000},"page":"1008-1016","source":"Crossref","is-referenced-by-count":12,"title":["Benfluorex (Mediator\u00ae) et atteintes valvulaires"],"prefix":"10.1016","volume":"40","author":[{"given":"Christophe","family":"Tribouilloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Jeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvestre","family":"Mar\u00e9chaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Jobic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rusinaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Andr\u00e9jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.09.001_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.09.001_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2011.09.001_bib0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0035","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-ht(2b) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2011.09.001_bib0040","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/eurheartj\/ehm263","article-title":"In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology","volume":"28","author":"Droogmans","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2011.09.001_bib0045","doi-asserted-by":"crossref","first-page":"H1940","DOI":"10.1152\/ajpheart.01177.2008","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study","volume":"296","author":"Droogmans","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.lpm.2011.09.001_bib0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/CIRCULATIONAHA.105.593459","article-title":"Serotonin transporter mechanisms and cardiac disease","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2011.09.001_bib0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2011.09.001_bib0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1157\/13043231","article-title":"Valvular heart disease associated with benfluorex","volume":"56","author":"Rafel Ribera","year":"2003","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.lpm.2011.09.001_bib0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2006.00441.x","article-title":"Valvular heart disease in a patient taking benfluorex","volume":"20","author":"Noize","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.lpm.2011.09.001_bib0070","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1183\/09031936.00086308","article-title":"Fenfluramine-like cardiovascular side-effects of benfluorex","volume":"33","author":"Boutet","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2011.09.001_bib0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.acvd.2009.09.015","article-title":"Valvular heart disease associated with benfluorex","volume":"103","author":"Gueffet","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.lpm.2011.09.001_bib0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ejechocard\/jeq172","article-title":"Valvular heart disease associated with benfluorex therapy: results from the French Multicentre Registry","volume":"12","author":"Le Ven","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.lpm.2011.09.001_bib0085","doi-asserted-by":"crossref","first-page":"e10128","DOI":"10.1371\/journal.pone.0010128","article-title":"Benfluorex and unexplained valvular heart disease: a case-control study","volume":"5","author":"Frachon","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2011.09.001_bib0090","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ejechocard\/jeq027","article-title":"Restrictive organic mitral regurgitation associated with benfluorex therapy","volume":"11","author":"Tribouilloy","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.lpm.2011.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus","volume":"19","author":"Weill","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lpm.2011.09.001_bib0100","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.lpm.2011.03.001","article-title":"Mortalit\u00e9 attribuable au benfluorex (Mediator\u00ae)","volume":"40","author":"Hill","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/diacare.29.03.06.dc05-1439","article-title":"Efficacy of benfluorex in combination with sulfonylurea in type 2\u00a0diabetic patients: an 18-week, randomized, double-blind study","volume":"29","author":"Moulin","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2011.09.001_bib0110","doi-asserted-by":"crossref","unstructured":"Boudes A, Lavoute C, Avierinos JF, Le Dolley Y, Villacampa C, Salem A, Loundou AD, Michel N, Renard S, Habib G. Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease. Eur J Echocardiogr 2011; doi:10.1093\/ejechocard\/jer116.","DOI":"10.1093\/ejechocard\/jer116"},{"key":"10.1016\/j.lpm.2011.09.001_bib0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ejechocard\/jep023","article-title":"Role of echocardiography in toxic heart valvulopathy","volume":"10","author":"Droogmans","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.lpm.2011.09.001_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-134-4-200102200-00008","article-title":"The progression of fenfluramine-associated valvular heart disease assessed by echocardiography","volume":"134","author":"Mast","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-136-6-200203190-00018","article-title":"Regression and progression of valvulopathy associated with fenfluramine and phentermine","volume":"136","author":"Dahl","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743\u00a0individuals","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.lpm.2011.09.001_bib0140","first-page":"230","article-title":"Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology","volume":"28","author":"Vahanian","year":"2007","journal-title":"Eur Heart J"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211004222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211004222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T07:51:20Z","timestamp":1560757880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498211004222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0755498211004222"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.09.001","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}